Led on site due diligence of clinical stage asset in neurology from a top tier pharmaceutical company

Situation: US biotech identified a clinical stage in-licensing opportunity under development by a large global pharma.  Confidential reports and documents were available for review on site only.


Solution:  Zebra assembled a team of experts including preclinical pharmacology and safety/toxicology, CMC, regulatory, clinical and Intellectual Property.  Our team coordinated a two-stage on-site due diligence of the drug dossier coordinating the effort and managing the final report drafting within the agreed deadline.  The activities included:


• Led due diligence activities and facilitated all communication between the two organizations, ensuring that the right subject matter experts were identified and consulted. 
• Managed the evaluation and transfer of information.
• Participated in the assessment of findings and daily status updates provided to senior management.
• Contributed clinically to recommendations provided to senior management and the Board of Directors 
• Developed risk adjusted NPV model to evaluate the product candidate
• Prepared Term sheet based on the product risks and valuation


Value:   Based on review of preclinical, clinical and patent data, Zebra provided final recommendation to the client and assisted the execution of term sheet as well as the licensing negotiation process.

Zebra Ventures Srl    Via Errico Petrella 22       20124 Milano
www.twozebras.com                  phone: +39 02 871 68 737              info@twozebras.com
P.IVA IT06550300963